Shots:

• Shionogi to receive an up front- milestones as well as royalties on sales of the therapy. BioAge to get exclusive US and EU rights to develop and commercialize BGE-17 for COVID-19
• Additionally- BioAge gets an exclusive right to negotiate a license for additional indications and plans to initiate P-II study of BGE-175 for COVID-19 in the H1’21
• BGE-175 is a DP1 receptor antagonist- developed for allergic rhinitis. The results of multiple non-clinical/ clinical trials in 2-400+ subjects & have shown that BGE-175 has high affinity and selectivity to the DP1 receptor1 & is well tolerated & safe

 ­ Ref: Shionogi | Image: Shionogi